We are live on ! Find out more
Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Portfolio holdings

AUM $59.8B
1-Year Est. Return 29.42%
This Fund
S&P 500
This Quarter Est. Return
+0.78%
1 Year Est. Return
+29.42%
3 Year Est. Return
+77.06%
5 Year Est. Return
+66.38%
10 Year Est. Return
+178.95%
AUM
$52.2B
AUM Growth
+$5.71B
Cap. Flow
+$5.97B
Cap. Flow %
11.44%
Top 10 Hldgs %
24.55%
Holding
3,166
New
373
Increased
1,842
Reduced
646
Closed
221

Sector Composition

Rank Sector Weight
1 Technology 12.58%
2 Financials 6.3%
3 Consumer Discretionary 4.54%
4 Healthcare 4.26%
5 Industrials 4.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SKYX icon
2901
SKYX Platforms
SKYX
$164M
$18.5K ﹤0.01%
15,946
IOBT
2902
DELISTED
IO Biotech
IOBT
$18.4K ﹤0.01%
+20,000
New +$19.9K
CRDL
2903
Cardiol Therapeutics
CRDL
$169M
$17.3K ﹤0.01%
13,538
-162
-1% -$273
ADAP
2904
DELISTED
Adaptimmune Therapeutics
ADAP
$14.4K ﹤0.01%
26,816
+16,000
+148% +$11.7K
OCGN icon
2905
Ocugen
OCGN
$444M
$11.7K ﹤0.01%
14,580
-93
-0.6% -$85
CYTH
2906
DELISTED
Cyclo Therapeutics, Inc. Common Stock
CYTH
$10.8K ﹤0.01%
18,285
-5,115
-22% -$3.55K
SBEV icon
2907
Splash Beverage Group
SBEV
$2.6M
$9.66K ﹤0.01%
375
FLG
2908
CALL
Flagstar Bank National Association
FLG
$5.84B
$8.89K ﹤0.01%
12,000
-1,000
-8% -$10.9K
NAK
2909
Northern Dynasty Minerals
NAK
$953M
$7.75K ﹤0.01%
13,322
+2
+0% +$1
VGZ icon
2910
Vista Gold
VGZ
$326M
$7.63K ﹤0.01%
13,675
QVCGA
2911
DELISTED
QVC Group Inc Series A
QVCGA
$7.29K ﹤0.01%
442
-70
-14% -$1.64K
VRCA icon
2912
Verrica Pharmaceuticals
VRCA
$88M
$7.09K ﹤0.01%
+1,013
New +$11.1K
CGTX icon
2913
Cognition Therapeutics
CGTX
$94M
$7.01K ﹤0.01%
+10,000
New +$4.94K
BB icon
2914
CALL
BlackBerry
BB
$5.18B
$7K ﹤0.01%
+10,000
New +$26.6K
VXRT
2915
DELISTED
Vaxart
VXRT
$6.76K ﹤0.01%
10,206
PTHS
2916
Pelthos Therapeutics
PTHS
$101M
$6.67K ﹤0.01%
1,040
XAIR icon
2917
Beyond Air
XAIR
$3.75M
$3.62K ﹤0.01%
25
TSCO icon
2918
PUT
Tractor Supply
TSCO
$18B
$3.56K ﹤0.01%
28,500
-16,000
-36% -$904K
BLRX
2919
BioLineRX
BLRX
$11.8M
$2.25K ﹤0.01%
263
MO icon
2920
CALL
Altria Group
MO
$109B
$12 ﹤0.01%
+24,800
New +$1.32M
ABBV icon
2921
PUT
AbbVie
ABBV
$438B
-13,300
Closed -$51.9K
ABT icon
2922
PUT
Abbott
ABT
$188B
-11,200
Closed -$40.5K
ACN icon
2923
PUT
Accenture
ACN
$109B
-2,800
Closed -$13K
AEO icon
2924
American Eagle Outfitters
AEO
$3.07B
-10,426
Closed -$233K
ALT icon
2925
CALL
Altimmune
ALT
$593M
-1,000
Closed -$606

Similar funds

Wealth Enhancement Advisory Services's Q4 2024 Portfolio in Review

As of Q4 2024, Wealth Enhancement Advisory Services held 3,166 positions worth $52.2B, up 12% from $46.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Wealth Enhancement Advisory Services deployed $5.97B of net new capital in Q4 2024, opening 373 new positions and adding to 1,842 existing holdings. Its largest new stake was Terex: 1,280,376 shares worth $59.2M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 12% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Vanguard Long-Term Treasury ETF, an estimated $343M trimmed.

  • Wealth Enhancement Advisory Services's largest Q4 2024 buy was Terex: 1,280,376 shares worth $59.2M.
  • Wealth Enhancement Advisory Services added most to iShares US Treasury Bond ETF in Q4 2024, an estimated $451M increase.
  • Wealth Enhancement Advisory Services's biggest Q4 2024 reduction was Vanguard Long-Term Treasury ETF, cutting an estimated $343M.
  • Wealth Enhancement Advisory Services fully exited Quadratic Interest Rate Volatility and Inflation Hedge ETF in Q4 2024, selling an estimated $13.7M.
  • Wealth Enhancement Advisory Services's ten largest holdings make up 25% of its $52.2B portfolio in Q4 2024.
  • Wealth Enhancement Advisory Services opened 373 new positions and closed 221 in Q4 2024.
  • Wealth Enhancement Advisory Services's portfolio value rose 12% quarter-over-quarter to $52.2B.

Based on Wealth Enhancement Advisory Services's 13F filing for Q4 2024, filed 10 Jan 2025.